Allogene Therapeutics, Inc. Impairment of Long-Lived Assets Held-for-use
Allogene Therapeutics, Inc. (ALLO) reported Impairment of Long-Lived Assets Held-for-use of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsHeldForUse · last filed 2026-08-12
- Allogene Therapeutics, Inc. impairment of long-lived assets held-for-use for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Allogene Therapeutics, Inc. impairment of long-lived assets held-for-use for the quarter ending 2025-12-31 was $0.00.
- Allogene Therapeutics, Inc. impairment of long-lived assets held-for-use for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Allogene Therapeutics, Inc. impairment of long-lived assets held-for-use for the quarter ending 2025-06-30 was $2.38M, a 52.25% decline year-over-year.
- Allogene Therapeutics, Inc. impairment of long-lived assets held-for-use for fiscal 2025 was $2.38M, a 84.84% decline from fiscal 2024.
- Allogene Therapeutics, Inc. impairment of long-lived assets held-for-use for fiscal 2024 was $15.72M, a 18.66% increase from fiscal 2023.
- Allogene Therapeutics, Inc. impairment of long-lived assets held-for-use for fiscal 2023 was $13.24M.
- Allogene Therapeutics, Inc. impairment of long-lived assets held-for-use for fiscal 2022 was $0.00.
| Period end | Impairment of Long-Lived Assets Held-for-use 3 month | Impairment of Long-Lived Assets Held-for-use 6 month | Impairment of Long-Lived Assets Held-for-use 9 month | Impairment of Long-Lived Assets Held-for-use 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-12 | $0.00 10-Q · filed 2026-08-12 | ||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $0.00 derived: sum of 2 quarters · filed 2026-03-12 | $2.38M derived: sum of 3 quarters · filed 2026-08-12 | $2.38M 10-K · filed 2026-03-12 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-06 | $2.38M derived: sum of 2 quarters · filed 2026-08-12 | $2.38M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $2.38M 10-Q · filed 2026-08-12 | $2.38M 10-Q · filed 2026-08-12 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $10.73M derived: sum of 2 quarters · filed 2026-03-12 | $15.72M derived: sum of 3 quarters · filed 2026-03-12 | $15.72M 10-K · filed 2026-03-12 |
| 2024-09-30 | $10.73M 10-Q · filed 2025-11-06 | $15.72M derived: sum of 2 quarters · filed 2025-11-06 | $15.72M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $4.99M 10-Q · filed 2025-08-13 | $4.99M 10-Q · filed 2025-08-13 | ||
| 2023-12-31 | $13.24M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $13.24M derived: sum of 2 quarters · filed 2025-03-13 | $13.24M derived: sum of 3 quarters · filed 2025-03-13 | $13.24M 10-K · filed 2025-03-13 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-07 | $0.00 10-Q · filed 2024-08-07 | ||
| 2022-12-31 | $0.00 10-K · filed 2024-03-14 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |